Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children

Soto, Jorge A.; Melo-González, Felipe; Gutiérrez-Vera, Cristián; Schultz, Bárbara M.; Berrios, Roslye V; Rivera-Pérez, Daniela; Piña-Iturbe, Alejandro; Hoppe-Elsholz, Guillermo; Duarte, Luisa F.; Vázquez, Yaneisi; Moreno-Tapia, Daniela; Ríos, Mariana; Játiva, Pablo Palacios; García-Betancourt, Richard; Santibáñez, Álvaro; Pacheco, Gaspar A; Méndez, Constanza; Andrade, Catalina A; Silva, Pedro H.; Diethelm‐Varela, Benjamín; Astudillo, Patricio; Calvo, Mario; Cárdenas, Antonio; González, Marcela; Goldsack, Macarena; Gutiérrez, Valentina; Potı́n, Marcela; Schilling, Andrea; Tapia, Lorena I.; Twele, Loreto; Villena, Rodolfo; Grifoni, Alba; Sette, Alessandro; Weiskopf, Daniela; Fasce, Rodrigo; Fernández, Jorge Onrubia; Mora, Judith; Ramı́rez, Eugenio; Gaete-Argel, Aracelly; Acevedo, Mónica L.; Valiente-Echeverría, Fernando; Soto-Rifo, Ricardo; Retamal-Díaz, Angello; Muñoz-Jofré, Nathalia; Xing, Meng; Xin, Qianqian; Alarcón-Bustamante, Eduardo; González-Aramúndiz, José Vicente; Corre, Nicole Le; Álvarez-Figueroa, María Javiera; González, Pablo A; Abarca, Katia; Perret, Cecilia; Carreño, Leandro J.; Bueno, Susan M.; Kalergis, Alexis M.

doi:10.1128/mbio.01311-22

Cited by 18 publications

(25 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, inactivated vaccines contain all the structural proteins in the SARS‐CoV‐2 virion, which may elicit multiprotein T cell responses. An activation‐induced marker expression assay revealed two doses of CoronaVac induced OX40 + CD137 + CD4 + T cells against S, N, and M in children aged 3–17 years 59 . The responses against S between children aged 3–11 and adolescents aged 12–17 were similar.…”

Section: Immune Responses To Inactivated Virus Vaccinesmentioning

confidence: 90%

“…Inactivated COVID‐19 vaccines also demonstrated robust antibody responses in pivotal trials 32,33,54–59 . The notable similarity between the inactivated and mRNA vaccines is that immune responses to both appeared to be age‐dependent.…”

Section: Immune Responses To Inactivated Virus Vaccinesmentioning

confidence: 94%

“…Younger children had higher antibody responses. After two doses of CoronaVac, children aged 3–11 years mounted significantly higher neutralization titers than adolescents aged 12–17 years 59 . Children aged 3–5 years who received three doses of WIBP‐CorV had the highest neutralization titers compared to children aged 6–12 years and 13–17 years 55 .…”

Section: Immune Responses To Inactivated Virus Vaccinesmentioning

confidence: 96%

“…Inactivated vaccines that target the ancestral SARS‐CoV‐2 also elicit antibody responses against VOCs in children and adolescents. Initially, significant reductions in neutralizing antibody titers against Omicron BA.1 after two doses of CoronaVac had been observed 59 . The drop was more significant in adolescents aged 12–17 than children aged 3–11, which again suggests an age‐dependent immune response 59 .…”

Section: Cross‐variant Reactivitymentioning

confidence: 99%

See 3 more Smart Citations

Immunogenicity of coronavirus disease 2019 vaccines in children: A review with ChatGPT

Leung

Duque

et al. 2023

Pediatric Discovery

View full text Add to dashboard Cite

SARS‐CoV‐2 causes millions of infection cases and coronavirus disease 2019 (COVID‐19)‐related deaths worldwide. In addition to acute illnesses, children and adolescents suffer from post‐infectious complications. Vaccination is a promising preventative treatment that can confer protection from these devastating outcomes. Utilizing ChatGPT, this review discusses the immunogenicity of mRNA and inactivated COVID‐19 vaccines in children and adolescents. Rapid vaccine discovery during the COVID‐19 pandemic led to the approval of the mRNA vaccines that stimulate potent antibody responses in pediatric population, and the younger age groups develop higher neutralizing and non‐neutralizing antibody responses than those who are older. Natural infection induces weaker antibody responses than vaccination. Vaccine‐induced humoral immunity decreases over time, as antibodies decline six months after the second dose. However, antibody avidity increases, which partly maintains neutralization and Fc‐effector functions that provide more durable protection. Inactivated COVID‐19 vaccines generate strong antibody responses in children and adolescents. They induce T cell responses against multiple structural protein antigens, although their neutralizing antibody responses appear weaker and wane more quickly than mRNA vaccines. Full‐dose intradermal administration and heterologous prime‐boost may improve the immunogenicity of inactivated vaccines. In children and adolescents, immune protection from the pre‐Omicron variants of concern (VOCs) is maintained. Vaccination induces less antibody neutralization against the Omicron variant, but non‐neutralizing antibodies and T cell responses persist. Hybrid immunity provides stronger immunogenicity against SARS‐CoV‐2 in the pediatric population. Future research must focus on long‐term immunity, interaction with breakthrough reinfections, cross‐reactivity against new VOCs, T cell immunogenicity and immunogenicity in young children.

show abstract

Section: Immune Responses To Inactivated Virus Vaccinesmentioning

confidence: 90%

Section: Immune Responses To Inactivated Virus Vaccinesmentioning

confidence: 94%

Section: Immune Responses To Inactivated Virus Vaccinesmentioning

confidence: 96%

Section: Cross‐variant Reactivitymentioning

confidence: 99%

See 2 more Smart Citations

Immunogenicity of coronavirus disease 2019 vaccines in children: A review with ChatGPT

Leung

Duque

et al. 2023

Pediatric Discovery

View full text Add to dashboard Cite

show abstract

“…Moreover, cytotoxic T cells can disinfect by killing virus-infected cells. Studies have confirmed that specific T-cell immunity targeting SARS-CoV-2 proteins plays an important role in viral clearance and prevention [78,79]. Some scholars found that neutralizing antibody levels significantly decreased in recovered patients > 3 months after infection, but T-lymphocyte immunity persisted after at least 10 months [80][81][82] and is expected to be maintained for many years [83].…”

Section: Coping Measuresmentioning

confidence: 93%

Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review

2022

View full text Add to dashboard Cite

Since the outbreak of the novel coronavirus disease 2019 (COVID-19) in 2019, many countries have successively developed a variety of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, with the continuous spread of SARS-CoV-2, it has evolved several variants; as a result, prevention and control of the pandemic of SARS-CoV-2 has become more important. Among these variants, the Omicron variant has higher transmissibility and immune escape ability and is the main variant causing a large number of COVID-19 breakthrough infection, thus, presenting new challenges to pandemic prevention and control. Hence, we review the biological characteristics of the Omicron variant and discuss the current status and possible mechanism of breakthrough infection caused by the Omicron variant in order to provide insights into the prevention and control of the pandemic of SARS-CoV-2.

show abstract

HIV-1-Based SARS-CoV-2 Pseudotyped Virus to Determine Neutralizing Antibody Titers in Chile

Gaete-Argel,

Acevedo,

Henriquez

et al. 2024

The Latin American Studies Book Series

View full text Add to dashboard Cite

Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children

Abstract: This work evaluated the immune response induced by two doses of CoronaVac separated by 4 weeks in healthy children and adolescents in Chile. To date, few studies have described the effects of CoronaVac in the pediatric population.

Cited by 18 publications

References 24 publications

Immunogenicity of coronavirus disease 2019 vaccines in children: A review with ChatGPT

Immunogenicity of coronavirus disease 2019 vaccines in children: A review with ChatGPT

Panorama of Breakthrough Infection Caused by SARS-CoV-2: A Review

HIV-1-Based SARS-CoV-2 Pseudotyped Virus to Determine Neutralizing Antibody Titers in Chile

Contact Info

Product

Resources

About